Explore daily insights on
Fulcrum Therapeutics Plunges 51% After Discontinuing Lead Sickle Cell Drug Over FDA Concerns
- Fulcrum Therapeutics suffered a massive selloff after halting its lead clinical program, pociredir, due to FDA concerns over malignancy risks.
- The stock plummeted 51.09% to close at $3.14 on June 2, while trading volume skyrocketed to 52.7 times its 20-day average.
- The discontinuation of its primary clinical asset represents a severe setback for the company's pipeline and raises doubts about its long-term viability.
Supporting datasets
Supporting queries
To surface this insight, Baselight ran 4 queries across its structured data. Each one is reproducible — open it, read the SQL, and rerun it yourself.
Conclusion
FULC close fell from $6.42 (June 1) to $3.14 (June 2) (-51.09%). Volume of 32,772,589 vs. 20-day average of 621,970 (52.7x ratio).